Ovarian Cancer
A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced non–HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)MK-5909-006
- Details
ClinicalTrials.gov ID:
NCT07776691
Diagnosis Type:
NA
USOR Number:
- Address
,
P: